[go: up one dir, main page]

PT1132403E - Peptidos inibidores de tgf g beta1 - Google Patents

Peptidos inibidores de tgf g beta1

Info

Publication number
PT1132403E
PT1132403E PT99957342T PT99957342T PT1132403E PT 1132403 E PT1132403 E PT 1132403E PT 99957342 T PT99957342 T PT 99957342T PT 99957342 T PT99957342 T PT 99957342T PT 1132403 E PT1132403 E PT 1132403E
Authority
PT
Portugal
Prior art keywords
tgf
beta1
inhibiting peptides
compositions
manufacture
Prior art date
Application number
PT99957342T
Other languages
English (en)
Inventor
Ezquerro Saenz Ignacio Jose
Lasarte Sagastibelza Juan Jose
Prieto Valtuena Jesus
Borras Cuesta Francisco
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of PT1132403E publication Critical patent/PT1132403E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT99957342T 1998-11-24 1999-11-23 Peptidos inibidores de tgf g beta1 PT1132403E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009802465A ES2146552B1 (es) 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31

Publications (1)

Publication Number Publication Date
PT1132403E true PT1132403E (pt) 2006-07-31

Family

ID=8305903

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99957342T PT1132403E (pt) 1998-11-24 1999-11-23 Peptidos inibidores de tgf g beta1

Country Status (16)

Country Link
US (2) US7057013B1 (pt)
EP (1) EP1132403B1 (pt)
JP (5) JP3836677B2 (pt)
CN (1) CN1203091C (pt)
AT (1) ATE322505T1 (pt)
AU (1) AU767498B2 (pt)
BR (1) BR9915604B1 (pt)
CA (1) CA2352537C (pt)
CY (1) CY1105616T1 (pt)
DE (1) DE69930763T2 (pt)
DK (1) DK1132403T3 (pt)
ES (2) ES2146552B1 (pt)
PT (1) PT1132403E (pt)
RU (1) RU2232771C2 (pt)
SI (1) SI1132403T1 (pt)
WO (1) WO2000031135A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) * 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
JP2002087938A (ja) * 2000-09-11 2002-03-27 Shiseido Co Ltd 養毛剤及びそのスクリーニング方法
WO2003093293A2 (en) * 2002-04-29 2003-11-13 Saint Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
AU2005337776B2 (en) * 2005-10-24 2013-01-31 Proyecto De Biomedicina Cima, S.L. Use of TGF-Beta1 inhibitor peptides in the preparation of an immune response modulating agent
RU2420307C2 (ru) * 2005-10-24 2011-06-10 Проекто Де Биомедисина Сима, С.Л. ПРИМЕНЕНИЕ ИНГИБИРУЮЩИХ TGF-бета1 ПЕПТИДОВ ДЛЯ ПРИГОТОВЛЕНИЯ МОДУЛИРУЮЩЕГО ИММУННЫЙ ОТВЕТ АГЕНТА
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Ｔｇｆｐ－ｃａｐ 펩타이드 및 그의 용도
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
EP2192904B1 (en) 2007-08-27 2016-08-17 Auxagen, Inc. METHODS FOR INHIBITING TGF-beta
JP4630914B2 (ja) 2008-04-14 2011-02-09 株式会社日本ハイポックス 肝線維化抑制剤
CN102123737B (zh) 2008-06-13 2014-01-01 西马生物医学计划公司 用于生物活性化合物施用的轭合物
EP2341913B1 (en) 2008-09-16 2014-11-19 Saint Louis University Method of enhancing tgf-beta signalling
CA2750559A1 (en) 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
ES2347627B1 (es) 2009-03-06 2011-10-10 Isdin, S.A. Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
KR100983182B1 (ko) 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
BR112012010755A2 (pt) 2009-11-05 2015-09-22 Proyecto Biomedicina Cima Sl constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
MX342270B (es) * 2010-02-18 2016-09-21 The Regents Of The Univ Of California * ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
EP2754719B1 (en) 2011-09-05 2018-08-29 Pola Pharma Inc. Method of using etfb as biomarker for identifying the growth state of fibroblasts
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
ES2786925T3 (es) 2013-03-14 2020-10-14 Brigham & Womens Hospital Inc Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales
MX386503B (es) 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
MX383328B (es) 2013-10-31 2025-03-13 Kyoto Prefectural Public Univ Corp Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea.
AU2014352843B2 (en) 2013-11-21 2020-03-05 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
KR20230019500A (ko) 2014-09-03 2023-02-08 더 브리검 앤드 우먼즈 하스피털, 인크. 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
AU2016301380B2 (en) 2015-08-04 2021-07-01 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
KR101841748B1 (ko) 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
KR101791526B1 (ko) 2016-02-18 2017-11-01 (주)케어젠 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
JP7080179B2 (ja) 2016-03-15 2022-06-03 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大に関する方法および組成物
JP7109446B2 (ja) 2016-12-30 2022-07-29 フリークエンシー セラピューティクス インコーポレイテッド 幹細胞／前駆支持細胞の自己複製を誘導するための１ｈ－ピロール－２，５－ジオン化合物およびその使用方法
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
KR101954214B1 (ko) * 2017-05-23 2019-03-06 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
TW202005981A (zh) 2018-07-11 2020-02-01 美商供石公司 高親和性、異構體選擇性之TGFβ1抑制劑及其用途
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
CN109432431B (zh) 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN113508111A (zh) 2018-12-31 2021-10-15 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
KR102265432B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
CN110511285B (zh) * 2019-08-27 2023-01-24 南京安吉生物科技有限公司 一种重组融合多肽及其应用
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
WO2022139493A1 (ko) * 2020-12-23 2022-06-30 한국과학기술연구원 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도
KR20240000395A (ko) * 2022-06-22 2024-01-02 주식회사 유씨아이테라퓨틱스 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
CA2086327A1 (en) * 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
FR2720069A1 (fr) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Dérivés de facteurs de croissance et d'hormones de la superfamille des TGFB, procédé pour leur obtention et leurs applications biologiques.
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy

Also Published As

Publication number Publication date
ATE322505T1 (de) 2006-04-15
JP4237807B2 (ja) 2009-03-11
ES2146552B1 (es) 2001-04-16
CA2352537A1 (en) 2000-06-02
DE69930763D1 (en) 2006-05-18
US7057013B1 (en) 2006-06-06
BR9915604B1 (pt) 2011-07-26
CY1105616T1 (el) 2010-07-28
JP4002287B2 (ja) 2007-10-31
JP3836677B2 (ja) 2006-10-25
JP2007186519A (ja) 2007-07-26
JP2002530431A (ja) 2002-09-17
CA2352537C (en) 2011-11-15
JP2008056685A (ja) 2008-03-13
US7528226B2 (en) 2009-05-05
DE69930763T2 (de) 2006-11-30
EP1132403B1 (en) 2006-04-05
RU2232771C2 (ru) 2004-07-20
ES2262349T3 (es) 2006-11-16
AU1507700A (en) 2000-06-13
CN1328569A (zh) 2001-12-26
JP2006241166A (ja) 2006-09-14
BR9915604A (pt) 2001-08-07
JP4068654B2 (ja) 2008-03-26
ES2146552A1 (es) 2000-08-01
US20070014767A1 (en) 2007-01-18
SI1132403T1 (sl) 2006-08-31
CN1203091C (zh) 2005-05-25
JP4272255B2 (ja) 2009-06-03
EP1132403A1 (en) 2001-09-12
AU767498B2 (en) 2003-11-13
JP2009040796A (ja) 2009-02-26
DK1132403T3 (da) 2006-08-14
WO2000031135A1 (es) 2000-06-02

Similar Documents

Publication Publication Date Title
PT1132403E (pt) Peptidos inibidores de tgf g beta1
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
CO4910133A1 (es) Antagonistas de 5-h[1f]
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
ATE386536T1 (de) Peptid zusammensetzungen und formulierungen unter verwendung derselben
EE9800306A (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
CA2123315A1 (en) Therapeutic agents which are antagonists or partial agonists of human interleukin 4
BR0207039A (pt) Polipeptìdeos de fusão da glicoproteìna ib alfa plaquetária e seus métodos de uso
NO20002408D0 (no) 5-HT1F antagonister
TR200200278T2 (tr) Kalsilitik bileşimler
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
DK1012286T3 (da) Allelvariant af humant STAT3
ZA989313B (en) Novel compounds for treating diseases associated with the biological effect of endothelin.
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
ZA971321B (en) Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamide useful for the treatment of allergic diseases.
ITRM920516A0 (it) Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi.